probenecid has been researched along with Heart Failure in 10 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Re-Prosper-HF study (Repurposing Probenecid for the Treatment of Heart Failure with Reduced Ejection Fraction) is a three-site double-blinded randomized-controlled trial that will test the hypothesis that probenecid can improve cardiac function in patients with HFrEF." | 9.51 | Repurposing Probenecid for the Treatment of Heart Failure (Re-Prosper-HF): a study protocol for a randomized placebo-controlled clinical trial. ( Bunke, J; Evans, K; Foster, G; Joseph, J; Luo, X; Mcconeghy, K; Onadeko, T; Parent, M; Robbins, N; Rubinstein, J; Wu, WC, 2022) |
| "The Re-Prosper-HF study (Repurposing Probenecid for the Treatment of Heart Failure with Reduced Ejection Fraction) is a three-site double-blinded randomized-controlled trial that will test the hypothesis that probenecid can improve cardiac function in patients with HFrEF." | 5.51 | Repurposing Probenecid for the Treatment of Heart Failure (Re-Prosper-HF): a study protocol for a randomized placebo-controlled clinical trial. ( Bunke, J; Evans, K; Foster, G; Joseph, J; Luo, X; Mcconeghy, K; Onadeko, T; Parent, M; Robbins, N; Rubinstein, J; Wu, WC, 2022) |
| " These initial studies demonstrate that tienilic acid is safe and effective in the treatment of mild to moderate essential hypertension, salt and water retention states, including oedema associated with congestive cardiac failure or mild to moderate renal dysfunction, and in the management of elevated serum uric acid levels associated with gout." | 5.04 | Safety of tienilic acid. ( Beg, MA; Ragland, R, 1979) |
| "Probenecid has been used for decades in the treatment of gout but recently has also been found to improve outcomes in patients with heart failure via stimulation of the transient receptor potential vanilloid 2 (TRPV2) channel in cardiomyocytes." | 3.96 | Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy. ( Koch, SE; Kranias, EG; Liu, G; McDermott, MR; Onusko, E; Robbins, N; Rubinstein, J, 2020) |
| "Probenecid was also able to reduce pressure overload-induced mortality and restore indices of disease severity in a rat chronic HF model in vivo." | 1.62 | AIM2-driven inflammasome activation in heart failure. ( Baranyai, T; Brenner, GB; Ferdinandy, P; Giricz, Z; Görbe, A; Gyöngyösi, M; Horváth, IG; Koncsos, G; Kucsera, D; Leszek, P; Makkos, A; Merkely, B; Novák, J; Onódi, Z; Radovits, T; Ruppert, M; Sayour, AA; Schulz, R; Tóth, VE; Varga, ZV, 2021) |
| " This article attempts to critically review these studies under seven different sections: furosemide pharmacokinetics in normal volunteers, furosemide pharmacokinetics in patients with decreased renal function, furosemide pharmacokinetics in patients with congestive heart failure, furosemide metabolism and assay methods, furosemide bioavailability, dose-response relationships, and the role of inhibitors and mediators on furosemide effects." | 1.26 | Pharmacokinetics/pharmacodynamics of furosemide in man: a review. ( Benet, LZ, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rubinstein, J | 4 |
| Robbins, N | 2 |
| Evans, K | 1 |
| Foster, G | 1 |
| Mcconeghy, K | 1 |
| Onadeko, T | 1 |
| Bunke, J | 1 |
| Parent, M | 1 |
| Luo, X | 1 |
| Joseph, J | 1 |
| Wu, WC | 1 |
| Onódi, Z | 3 |
| Koch, S | 2 |
| Ferdinandy, P | 3 |
| Varga, ZV | 3 |
| Onusko, E | 1 |
| McDermott, MR | 1 |
| Liu, G | 1 |
| Kranias, EG | 1 |
| Koch, SE | 1 |
| Ruppert, M | 1 |
| Kucsera, D | 1 |
| Sayour, AA | 1 |
| Tóth, VE | 1 |
| Koncsos, G | 1 |
| Novák, J | 1 |
| Brenner, GB | 1 |
| Makkos, A | 1 |
| Baranyai, T | 1 |
| Giricz, Z | 1 |
| Görbe, A | 1 |
| Leszek, P | 1 |
| Gyöngyösi, M | 1 |
| Horváth, IG | 1 |
| Schulz, R | 1 |
| Merkely, B | 1 |
| Radovits, T | 1 |
| Kang, EH | 1 |
| Kim, SC | 1 |
| BRONSKY, D | 1 |
| DUBIN, A | 1 |
| KUSHNER, DS | 1 |
| SILBERSTEIN, EB | 1 |
| Beg, MA | 1 |
| Ragland, R | 1 |
| Benet, LZ | 1 |
| Carroll, KF | 1 |
| Long, FL | 1 |
| Smith, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Veterans With Heart Failure With Reduced Ejection Fraction With Probenecid[NCT04551222] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2021-06-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for probenecid and Heart Failure
| Article | Year |
|---|---|
Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Drug Repositioning; Heart Failure; Humans; Myocard | 2023 |
Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Drug Repositioning; Heart Failure; Humans; Myocard | 2023 |
Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Drug Repositioning; Heart Failure; Humans; Myocard | 2023 |
Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Drug Repositioning; Heart Failure; Humans; Myocard | 2023 |
Cardiovascular Safety of Urate Lowering Therapies.
Topics: Allopurinol; Cardiovascular Diseases; Endothelium; Febuxostat; Gout; Gout Suppressants; Heart Failur | 2019 |
2 trials available for probenecid and Heart Failure
| Article | Year |
|---|---|
Repurposing Probenecid for the Treatment of Heart Failure (Re-Prosper-HF): a study protocol for a randomized placebo-controlled clinical trial.
Topics: Calcium; Heart Failure; Humans; Probenecid; Randomized Controlled Trials as Topic; Stroke Volume; Ve | 2022 |
Safety of tienilic acid.
Topics: Clinical Trials as Topic; Glycolates; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Kidn | 1979 |
6 other studies available for probenecid and Heart Failure
| Article | Year |
|---|---|
Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy.
Topics: Animals; Apoptosis; Calcium Channels; Cardiomyopathies; Disease Models, Animal; Echocardiography; Fe | 2020 |
AIM2-driven inflammasome activation in heart failure.
Topics: Adolescent; Adult; Aged; Animals; Calcium-Binding Proteins; CARD Signaling Adaptor Proteins; Case-Co | 2021 |
Diuretic action of benemid; its effect upon the urinary excretion of sodium, chloride, potassium and water in edematous subjects.
Topics: Diuresis; Diuretics; Edema; Electrolytes; Heart Failure; Humans; Kidney Diseases; Potassium; Probene | 1955 |
ERYSIPELOTHRIX ENDOCARDITIS: REPORT OF A CASE WITH CEREBRAL MANIFESTATIONS.
Topics: Brain Diseases; Chloramphenicol; Chlorothiazide; Digoxin; Diuretics; Drug Therapy; Endocarditis; End | 1965 |
Pharmacokinetics/pharmacodynamics of furosemide in man: a review.
Topics: Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Furosemide; Heart Fail | 1979 |
Complications in a patient with subacute bacterial endocarditis with particular reference to massive penicillin therapy.
Topics: Blood Protein Electrophoresis; Calcinosis; Embolism; Endocarditis, Subacute Bacterial; Femoral Arter | 1969 |